SYShota Yamamoto

Shota Yamamoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shota Yamamoto has a total of 135 co-authors. Here are the top co-authors by number of shared publications:

  • Terumitsu Hasebe

    Department of Radiology, Tokai University Hachioji Hospital, Tokai University School of Medicine, 1838 Ishikawa-machi, Hachioji , Tokyo , Japan

    6 shared publications
  • Fumio Sakamaki

    Department of Respiratory Medicine, Tokai University Hachioji Hospital, Ishikawa-machi 1838, Hachioji, Tokyo, 192-0032, Japan

    5 shared publications
  • Shunsuke Kamei

    Department of Radiology Tokai University Hachioji Hospital, Tokai University School of Medicine Tokyo Japan

    5 shared publications
  • Haruhito Sugiyama

    Department of Respiratory Medicine, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan

    4 shared publications
  • Konomi Kobayashi

    Department of Respiratory Medicine, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan

    4 shared publications
  • Masayuki Hojo

    Respiratory Disease Center, NTT Medical Center Tokyo, 5-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo, 141-8625, Japan

    4 shared publications

Latest Publications

  • Open Access

    Identifying effect modifiers of corticosteroids in acute respiratory distress syndrome: a meta-regression analysis of randomized controlled trials

    by Naoki Fukunaga, Takuya Wada, Yusuke Naito, Satoshi Hokari, Satoshi Okamori, Shota Yamamoto

    Systemic corticosteroids are administered in acute respiratory distress syndrome (ARDS) for their anti-inflammatory effects. However, the factors that influence their therapeutic efficacy remain poorly understood. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating corticosteroid therapy in adults with non-COVID ARDS. Comprehensive searches of PubMed, CENTRAL, and Web of Science were performed through October 2024. A random-effects model was used to pool the risk ratios (RRs) for short-term all-cause mortality. Inverse-variance-weighted univariable meta-regression analyses were conducted to assess associations between study-level characteristics and treatment effects. Subgroup analysis was performed based on the era of lung-protective ventilation (LPV) adoption using a random-effects model. Adverse events including intensive care unit (ICU)-acquired weakness, superinfection, and barotrauma were also evaluated. The credibility of subgroup effects was evaluated using Instrument for assess the Credibility of Effect Modification Analyses (ICEMAN), and certainty of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Eleven RCTs encompassing 1,441 patients met inclusion criteria. Meta-regression identified year of publication as the only potential of effect modifier (coefficient: -0.014; 95% confidence interval [CI]: -0.031 to 0.002; p = 0.082). Subgroup analysis of short-term mortality showed a lower RR in trials conducted after LPV implementation (RR 0.65; 95% CI: 0.50 to 0.86) than in earlier trials (RR 0.86; 95% CI: 0.73 to 1.02), although a between-subgroup difference was not apparent (p = 0.095). Both ICEMAN credibility of subgroup effect and GRADE certainty of evidence were moderate. A sensitivity analysis using the longest available mortality time point showed a consistent directional pattern (RR 0.71; 95% CI 0.54 to 0.94 after LPV, compared with RR 0.86; 95% CI 0.73 to 1.01 before LPV; p = 0.253). Analyses of adverse events suggested a potential increase in ICU-acquired weakness, no clear increase in superinfection, and a possible reduction in barotrauma. Benefit appears larger in more recent trials conducted in the LPV era; this may reflect improvements in ventilatory care, optimization of steroid regimens, and other secular changes in non-COVID ARDS, highlighting the need for further stratified research. PROSPERO CRD42024597366. The online version contains supplementary material available at 10.1186/s12890-026-04236-9.

  • Open Access

    Comparison of oxygenation targets in critically ill adults: a systematic review and network meta-analysis of randomized controlled trials

    by Ryosuke Imai, Ryohei Yamamoto, Takayuki Niitsu, Ann-Marcia C Tukpah, Ryo Kamidani, Hiroki Sato, Yohei Iwasaki, Haruna Kodama, Yutaro Shinzato, Jun Kataoka, et al.

    Ryosuke Imai, MD, MMSc, Ryohei Yamamoto, MD, PhD, Takayuki Niitsu, MD, Ann-Marcia C Tukpah, MD, MPH, MS, Ryo Kamidani, MD, PhD, Hiroki Sato, PhD, Yohei Iwa


  • Efficacy of Antiinflammatory Therapies for Adults With Non-Cystic Fibrosis Bronchiectasis

    by Shota Yamamoto, Takayuki Niitsu, Kiyoharu Fukushima, Ayako Shiozawa, Ryosuke Imai, Kazuki Hashimoto, Kenneth N. Olivier, Timothy R. Aksamit, Kozo Morimoto


  • Open Access

    Comparison of Corticosteroid Regimens for COVID-19 and Non-COVID-19 ARDS

    by Ryosuke Imai, Takayuki Niitsu, Monica Yun Liu, Hilary Faust, Lynn M. Schnapp, Shota Yamamoto


  • Surgical and Bronchoscopic Lung Volume Reduction for Severe Emphysema: A Systematic Review and Network Meta-analysis

    by Shota Yamamoto, Nobuyuki Horita, Ryosuke Imai, Takayuki Niitsu

    Background Along with lung volume reduction surgery (LVRS), bronchoscopic lung volume reduction is a treatment option for end-stage emphysema. However, comparisons among interventions remain insufficient. Methods We searched on PubMed, CENTRAL, Embase, and Web of Science. We included randomized controlled trials with outcomes measuring mid-term mortality within 6 months, changes in forced expiratory volume in one second (FEV1), St. George’s Respiratory Questionnaire (SGRQ), six-minute walk distance (6MWD) from baseline, adverse event related to procedures, and long-term mortality within 5 years. Bayesian network meta-analysis was performed. The certainty was assessed by CINeMA. Results Twenty-five randomized controlled trials involving 4,283 patients were included, identifying seven types of procedures and standard of care. Mid-term mortality increased in LVRS and endobronchial valve (EBV) (LVRS, risk ratio [RR] 3.26, 95% CrI 1.98–6.21, low certainty; EBV, RR 2.06 95% CrI 1.07–4.36, moderate certainty). LVRS showed the largest improvements: change in FEV1 (187.2 mL, 95% CrI 166.4–209.6), 6MWD (42.2 m, 95% CrI 33.2–50.5), and SGRQ (− 13.29 points, 95% CrI − 27.25–0.75). Among bronchoscopic procedures, high efficacy was noted in EBV and endobronchial coil (EBC) for FEV1 changes (EBV, 111.8 mL, 95% CrI 92.2–136.2; EBC, 74.1 mL, 95% CrI 47.6–101.7). Pneumothorax increased in these two procedures (EBV, RR 12.75, 95% CrI 5.52–35.48; EBC, RR 4.95, 95% CrI 1.12–40.90). Conclusion LVRS offers high efficacies but is accompanied by increased mid-term mortality. EBV and EBC also showed effectiveness; however, they increased pneumothorax, and EBV slightly increased mortality. For accurate assessment, long-term survival data of BLVR are needed.


  • Sputum colour matters: haemoptysis in a bronchiectasis registry

    by Shota Yamamoto, Hideo Ishikawa, Keita Takeda, Masahiro Kawashima

    Shareable abstract Expansion of sputum data categorisation in future bronchiectasis registries may lead to appropriate assessment of exacerbations and identification of severe phenotypeshttps://bit.ly/3JElUFh

  • Benefit-Risk Profile of P2X3 Receptor Antagonists for Treatment of Chronic Cough

    by Shota Yamamoto, Nobuyuki Horita, Johsuke Hara, Mao Sasamoto, Yoshihiro Kanemitsu, Yu Hara, Yasushi Obase, Takeshi Kaneko, Akio Niimi, Hiroshi Mukae


  • Potential of Muscle Mass Evaluation for Prognostic Prediction of COVID-19

    by Shota Yamamoto, Chikamasa Ichita

  • Retracted
    Open Access

    Retracted: Chest digital dynamic radiography to detect changes in human pulmonary perfusion in response to alveolar hypoxia

    by Shota Yamamoto, Fumio Sakamaki, Genki Takahashi, Yusuke Kondo, Naoya Taguchi, Shogo Esashi, Ryotaro Yuji, Katsuki Murakami, Kensuke Osaragi, Kosuke Tomita, et al.

    Introduction: Hypoxic pulmonary vasoconstriction optimises oxygenation in the lung by matching the local‐blood perfusion to local‐ventilation ratio upon exposure to alveolar hypoxia. It plays an important role in various pulmonary diseases, but few imaging evaluations of this phenomenon in humans. This study aimed to determine whether chest digital dynamic radiography could detect hypoxic pulmonary vasoconstriction as changes in pulmonary blood flow in healthy individuals.Methods: Five Asian men underwent chest digital dynamic radiography before and after 60 sec breath‐holding at the maximal inspiratory level in upright and supine positions. Alveolar partial pressure of oxygen and atmospheric pressure were calculated using the blood gas test and digital dynamic radiography imaging, respectively. To evaluate the blood flow, the correlation rate of temporal change in each pixel value between the lung fields and left cardiac ventricles was analysed.Results: Sixty seconds of breath‐holding caused a mean reduction of 26.7 ± 6.4 mmHg in alveolar partial pressure of oxygen. The mean correlation rate of blood flow in the whole lung was significantly lower after than before breath‐holding (before, upright 51.5%, supine 52.2%; after, upright 45.5%, supine 46.1%; both P < 0.05). The correlation rate significantly differed before and after breath‐holding in the lower lung fields (upright, 11.8% difference; supine, 10.7% difference; both P < 0.05). The mean radiation exposure of each scan was 0.98 ± 0.09 mGy. No complications occurred.Conclusions: Chest digital dynamic radiography could detect the rapid decrease in pulmonary perfusion in response to alveolar hypoxia. It may suggest hypoxic pulmonary vasoconstriction in healthy individuals.